Astellas, Anokion Announce $760M Development Deal

Jun 03, 2015

GEN

Astellas Pharma and Anokion said they will collaborate on research of new treatments for type 1 diabetes and celiac disease, and possibly a third indication, in a deal up to $760 million for Anokion, according to a GEN article.

The companies would create a new company, Kanyos Bio, to develop clinical candidates in type 1 diabetes and celiac disease, with Astellas holding an option to add a third autoimmune indication as part of the collaboration. Read the full story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments